The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease’s slow progression.

Beginning this week, Vanderbilt men will have a good excuse to ignore their razors and let their facial hair grow. November has been dubbed “Movember,” a time when men are encouraged to grow a moustache to raise funds and awareness for prostate cancer.

A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the U.S. declined 28 percent in the year following the draft recommendation from the United States Preventive Services Task Force against routine PSA screening for men.

Austin Kirschner, M.D., Ph.D., assistant professor of Radiation Oncology and Cancer Biology, has received the Urology Care Foundation Research Scholars Award for the study of advanced prostate cancer.

Vanderbilt-Ingram Cancer Center (VICC) patient William Ostman smiled while gazing into a camera lens and declared, “I am a prostate cancer survivor.”

Vanderbilt University researcher William Mitchell, M.D., Ph.D., and colleagues in Germany and Canada have demonstrated a method for detecting “cell-free” tumor DNA in the bloodstream.

A combination of two types of therapy may be more effective in treating castration-resistant prostate cancer.